Theravance Biopharma (NASDAQ:TBPH) Receives Buy Rating from HC Wainwright

Theravance Biopharma (NASDAQ:TBPH)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report released on Monday, Benzinga reports. They presently have a $15.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 84.28% from the stock’s current price.

TBPH has been the subject of a number of other research reports. Leerink Partnrs downgraded Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 6th. TD Cowen dropped their target price on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. Leerink Partners lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $15.00 to $10.00 in a report on Tuesday, August 6th. Finally, StockNews.com downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Theravance Biopharma presently has a consensus rating of “Hold” and an average target price of $13.75.

Theravance Biopharma Trading Up 0.4 %

Shares of NASDAQ:TBPH opened at $8.14 on Monday. The company has a 50 day moving average of $8.79 and a 200 day moving average of $8.89. The stock has a market cap of $398.21 million, a P/E ratio of -9.47 and a beta of 0.24. Theravance Biopharma has a 12 month low of $7.44 and a 12 month high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 21.29%. The firm had revenue of $14.26 million for the quarter, compared to analysts’ expectations of $15.81 million. During the same quarter last year, the firm earned ($0.28) earnings per share. On average, equities analysts forecast that Theravance Biopharma will post -1.04 earnings per share for the current fiscal year.

Insider Activity at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 335,965 shares of the company’s stock, valued at $3,023,685. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now owns 335,965 shares in the company, valued at $3,023,685. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Eli Samaha bought 999,800 shares of the stock in a transaction dated Wednesday, August 7th. The stock was bought at an average cost of $7.80 per share, with a total value of $7,798,440.00. Following the purchase, the insider now owns 9,511,150 shares in the company, valued at approximately $74,186,970. The disclosure for this purchase can be found here. 6.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in TBPH. China Universal Asset Management Co. Ltd. increased its holdings in Theravance Biopharma by 66.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,583 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 3,824 shares during the period. Hsbc Holdings PLC purchased a new position in shares of Theravance Biopharma during the second quarter valued at approximately $108,000. Gerber LLC bought a new position in shares of Theravance Biopharma during the fourth quarter valued at approximately $112,000. XTX Topco Ltd purchased a new stake in Theravance Biopharma in the second quarter worth $129,000. Finally, State Board of Administration of Florida Retirement System boosted its holdings in Theravance Biopharma by 28.2% in the first quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 4,990 shares in the last quarter. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.